Welcome to our dedicated page for Evotec SEC filings (Ticker: EVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles Evotec SE (EVO) filings with the U.S. Securities and Exchange Commission, giving investors structured access to the company’s regulatory disclosures. As a foreign private issuer, Evotec files its annual report on Form 20-F and submits interim information and material updates on Form 6-K.
Recent Form 6-K submissions referenced in the company’s disclosures include reports on financial results for the first half and first nine months of 2025, adjustments to revenue guidance while confirming profit guidance, and details of a share repurchase program. Other 6-Ks transmit press releases on strategic transactions, such as the planned and then finalized agreements with Sandoz regarding the Just - Evotec Biologics Toulouse site and an indefinite license to Evotec’s continuous manufacturing platform technology.
Additional 6-K filings cover business updates on Evotec’s strategy for sustainable and profitable growth, including the renaming of its Shared R&D segment to Discovery & Preclinical Development, progress in collaborations with Bristol Myers Squibb and Bayer, and the evolution of Just - Evotec Biologics toward an asset-lighter, technology-centric model.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that clarify key points from lengthy filings. This includes context on revenue mix, cost initiatives, strategic partnerships, and capital allocation measures such as buybacks. For deeper analysis, investors can focus on how Evotec describes its platform technologies, partnered R&D asset portfolio, and guidance for future periods within its official filings.
Evotec SE received a Schedule 13G filing from investment entities associated with MAK Capital, disclosing a significant passive ownership position. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 9,386,434 Ordinary Shares, representing 5.3% of Evotec’s Ordinary Shares outstanding as of January 9, 2026, based on the issuer’s website disclosure of 177,778,907 shares. The reporting persons indicate they hold shared power to vote and dispose of these shares and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Evotec SE.
Evotec SE filed a Form 6-K noting that on January 16, 2026 it submitted several Notifications of Major Holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht. These notifications, which disclose significant shareholdings under German law, are attached as Exhibits 99.1, 99.2 and 99.3. Exhibit 99.1 and 99.2 relate to notifications identified with “GS” dated January 13, 2026 and January 9, 2026, respectively, and Exhibit 99.3 relates to a notification identified with “MAK” dated January 9, 2026. The report is signed on behalf of Evotec SE by Chief Executive Officer Christian Wojczewski.
Evotec SE filed a Form 6-K as a foreign private issuer to inform investors that it submitted two Notifications of Major Holdings to the German financial regulator Bundesanstalt für Finanzdienstleistungsaufsicht.
These notifications, dated January 13, 2026 (Exhibit 99.1, MAK) and January 12, 2026 (Exhibit 99.2, Triton), are attached as exhibits to the report.
Evotec SE reported that its Seattle-based subsidiary, Just – Evotec Biologics, has received a new grant from the Gates Foundation to support global access to biotherapeutics. The funding will use the company’s AI-driven J.MD™ molecular design service, part of its J.DESIGN™ platform, to improve the developability of monoclonal antibodies so they can be manufactured more efficiently and at lower cost for low- and middle-income countries.
The grant will fund 10 new J.MD™ projects over the next three years, targeting multiple global health disease indications and building on work since 2014 that has included cGMP manufacturing campaigns for RSV, malaria, and HIV antibodies. Evotec also notes that it submitted a Notification of Major Holdings to the German financial regulator, attached as a separate exhibit.
Evotec SE reported that it has submitted Notifications of Major Holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht, in accordance with German law. These notifications, related to JPM and provided as Exhibits 99.1 and 99.2, are being shared with investors through this Form 6-K so the market is informed about significant shareholding positions.
Evotec SE filed a Form 6-K announcing that its management resolved on November 06, 2025 to implement a share repurchase program. The company states that the program is described in Exhibit 99.1, an announcement made pursuant to Article 5(1)(a) of Regulation (EU) No. 596/2014 and Article 2(1) of Delegated Regulation (EU) No. 2016/1052.
This is an administrative disclosure indicating the company’s decision to buy back shares, with specific terms set out in the accompanying exhibit.
Evotec SE furnished a report for investors summarizing that it has released its financial results and business updates for the first nine months of 2025. The company states that these details are contained in a press release attached as Exhibit 99.1 to this report.
The exhibit is titled “Evotec SE reports 9M 2025 results: Continued strong execution on strategic priorities,” indicating that management views its progress on key strategic goals as ongoing. The report is signed by the Chief Financial Officer, Paul Hitchin.
Evotec SE reported it has signed a final agreement with Sandoz. According to the company’s announcement, the transaction could result in payments potentially over US$ 650 m, plus royalties tied to a portfolio of up to 10 biosimilar molecules.
The update was furnished via a Form 6-K alongside a press release. The disclosure highlights the scale of the collaboration and the royalty-bearing structure on a multi-asset biosimilar portfolio, indicating a broad, long-term commercial framework with Sandoz.
Evotec SE filed a Form 6-K to furnish a press release covering its financial results and business updates for the first six months of 2025. The release, dated August 13, 2025 and attached as Exhibit 99.1, is titled “Evotec SE reports H1 2025 results: Strong progress on strategy execution.”
This filing mainly serves to formally provide that press release to investors and regulators and indicates that Evotec reports annually on Form 20-F.
FAQ
What is the current stock price of Evotec (EVO)?
What is the market cap of Evotec (EVO)?
